AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Imugene Limited has secured a Notice of Allowance relating a US patent application for its B-cell activating immunotherapy PD1-Vaxx.
- PD1-Vaxx is undergoing clinical development for non-small cell lung cancer.
- The patent titled “HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF” protects to 2038.
Shares of ASX-listed clinical-stage immuno-oncology company Imugene Limited (ASX:IMU) rose by over 5.5% to reach AU$0.142 midday on 10 February 2023, with a market capitalisation of AU$866.93 million.
The share price jumped following an upbeat company announcement. Imugene has been given a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application concerning its B-cell activating immunotherapy PD1-Vaxx. At present, PD1-Vaxx is being studied in patients with non-small cell lung cancer (NSCLC).
Data source: Company update
Patent details
Title of the patent: “HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF”
The patent holds validity till 2038, protecting the composition of matter and treatment process in cancer of IMU’s PD1- Vaxx for the generation of a therapeutic antibody response against the programmed death-1 (PD1) checkpoint target.
Phase 1b trial
The phase 1b trial is titled “An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab, in Adults with Non-Small Cell Lung Cancer.” It is being conducted with the objectives of examining safety, efficacy, as well as optimal dose of PD1-Vaxx when combined with atezolizumab (Tecentriq®), an immune checkpoint inhibitor (ICI) targeting PD-L1 in non-small cell lung cancer patients.
Currently, preparations are in the final phase to conduct the clinical study at sites across Australia and the United States.
Image source: Company presentation
Management commentary
